775 related articles for article (PubMed ID: 17545546)
21. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
22. TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death.
Lee J; An S; Choi YM; Jung JH; Li L; Meng H; Dong Y; Ahn KJ; An IS; Bae S
J Cell Biochem; 2017 Jul; 118(7):1733-1740. PubMed ID: 27935098
[TBL] [Abstract][Full Text] [Related]
23. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells.
Shen H; Moran DM; Maki CG
Cancer Res; 2008 Oct; 68(20):8260-8. PubMed ID: 18922897
[TBL] [Abstract][Full Text] [Related]
24. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
[TBL] [Abstract][Full Text] [Related]
25. Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.
Trino S; Iacobucci I; Erriquez D; Laurenzana I; De Luca L; Ferrari A; Ghelli Luserna Di Rorà A; Papayannidis C; Derenzini E; Simonetti G; Lonetti A; Venturi C; Cattina F; Ottaviani E; Abbenante MC; Russo D; Perini G; Musto P; Martinelli G
Oncotarget; 2016 Mar; 7(11):12951-61. PubMed ID: 26887044
[TBL] [Abstract][Full Text] [Related]
26. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
27. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
Drakos E; Atsaves V; Li J; Leventaki V; Andreeff M; Medeiros LJ; Rassidakis GZ
Leukemia; 2009 Apr; 23(4):784-90. PubMed ID: 19225536
[TBL] [Abstract][Full Text] [Related]
28. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.
Michaelis M; Rothweiler F; Klassert D; von Deimling A; Weber K; Fehse B; Kammerer B; Doerr HW; Cinatl J
Cancer Res; 2009 Jan; 69(2):416-21. PubMed ID: 19147553
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
[TBL] [Abstract][Full Text] [Related]
30. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension.
Mouraret N; Marcos E; Abid S; Gary-Bobo G; Saker M; Houssaini A; Dubois-Rande JL; Boyer L; Boczkowski J; Derumeaux G; Amsellem V; Adnot S
Circulation; 2013 Apr; 127(16):1664-76. PubMed ID: 23513067
[TBL] [Abstract][Full Text] [Related]
31. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
33. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.
Gu L; Zhu N; Findley HW; Zhou M
Leukemia; 2008 Apr; 22(4):730-9. PubMed ID: 18273046
[TBL] [Abstract][Full Text] [Related]
34. Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy.
Das M; Dilnawaz F; Sahoo SK
Nanomedicine (Lond); 2011 Apr; 6(3):489-507. PubMed ID: 21542687
[TBL] [Abstract][Full Text] [Related]
35. An Mdm2 antagonist, Nutlin-3a, induces p53-dependent and proteasome-mediated poly(ADP-ribose) polymerase1 degradation in mouse fibroblasts.
Matsushima S; Okita N; Oku M; Nagai W; Kobayashi M; Higami Y
Biochem Biophys Res Commun; 2011 Apr; 407(3):557-61. PubMed ID: 21419099
[TBL] [Abstract][Full Text] [Related]
36. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.
Sonnemann J; Palani CD; Wittig S; Becker S; Eichhorn F; Voigt A; Beck JF
Eur J Cancer; 2011 Jun; 47(9):1432-41. PubMed ID: 21334198
[TBL] [Abstract][Full Text] [Related]
37. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
38. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
[TBL] [Abstract][Full Text] [Related]
39. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
Kojima K; Konopleva M; Samudio IJ; Ruvolo V; Andreeff M
Cancer Res; 2007 Apr; 67(7):3210-9. PubMed ID: 17409429
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
